- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2041-1723
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma ; volume:8 ; number:1 ; day:22 ; month:12 ; year:2017 ; pages:1-13 ; date:12.2017
Nature Communications ; 8, Heft 1 (22.12.2017), 1-13, 12.2017
- Urheber
-
Bertrand, Florie
Montfort, Anne
Marcheteau, Elie
Imbert, Caroline
Gilhodes, Julia
Filleron, Thomas
Rochaix, Philippe
Andrieu-Abadie, Nathalie
Levade, Thierry
Meyer, Nicolas
Colacios, Céline
Ségui, Bruno
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41467-017-02358-7
- URN
-
urn:nbn:de:101:1-2019070801491576996156
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 07:33 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Bertrand, Florie
- Montfort, Anne
- Marcheteau, Elie
- Imbert, Caroline
- Gilhodes, Julia
- Filleron, Thomas
- Rochaix, Philippe
- Andrieu-Abadie, Nathalie
- Levade, Thierry
- Meyer, Nicolas
- Colacios, Céline
- Ségui, Bruno
- SpringerLink (Online service)
Ähnliche Objekte (12)
Management of Localized Melanoma in the Anti-PD-1 Era
Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone
Analysis of T cell responses during anti-PD-1 & anti-CTLA-4 dual blockade therapy and anti-PD-1 monotherapy in stage III/IV metastatic melanoma patients
Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment
Comprehensive molecular and clinical characterization of Asian melanoma patients treated with anti-PD-1 antibody
m6A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade
Interim [18F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
Vogt-Koyanagi-Harada Disease-Like Uveitis during Nivolumab (Anti-PD-1 Antibody) Treatment for Metastatic Cutaneous Malignant Melanoma
Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients
Management of Localized Melanoma in the Anti-PD-1 Era
Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone
Analysis of T cell responses during anti-PD-1 & anti-CTLA-4 dual blockade therapy and anti-PD-1 monotherapy in stage III/IV metastatic melanoma patients
Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment
Comprehensive molecular and clinical characterization of Asian melanoma patients treated with anti-PD-1 antibody
m6A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade
Interim [18F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
Vogt-Koyanagi-Harada Disease-Like Uveitis during Nivolumab (Anti-PD-1 Antibody) Treatment for Metastatic Cutaneous Malignant Melanoma
Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients
Management of Localized Melanoma in the Anti-PD-1 Era
Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone
Analysis of T cell responses during anti-PD-1 & anti-CTLA-4 dual blockade therapy and anti-PD-1 monotherapy in stage III/IV metastatic melanoma patients
Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment
Comprehensive molecular and clinical characterization of Asian melanoma patients treated with anti-PD-1 antibody
m6A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade
Interim [18F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
Vogt-Koyanagi-Harada Disease-Like Uveitis during Nivolumab (Anti-PD-1 Antibody) Treatment for Metastatic Cutaneous Malignant Melanoma